Clinical Trials Logo

Leiomyoma clinical trials

View clinical trials related to Leiomyoma.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06325501 Recruiting - Myoma;Uterus Clinical Trials

Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy

Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

Uterine leiomyomas, or fibroids, are common benign tumors among women, especially those over 35 years old. They can cause various issues, including heavy menstrual bleeding, anemia, pelvic pain, and pressure symptoms. Surgery is often necessary for symptomatic fibroids, with hysterectomy recommended for women over 40 and myomectomy for those wishing to preserve their uterus. Myomectomy can be performed using different surgical approaches but can be associated with significant morbidity, particularly major blood loss, especially in abdominal myomectomy, where up to 20% of women may require blood transfusion. Various interventions have been introduced to reduce bleeding during myomectomy, such as tourniquets, bupivacaine plus epinephrine infiltration, vasopressin injection, preoperative GnRH agonist administration, and preoperative ascorbic acid injection. However, these strategies may have complications, be ineffective, expensive, or require extra steps. Oxytocin, primarily secreted from the pituitary gland, is crucial for uterine contraction during labor and delivery, and is used to prevent postpartum uterine atony and bleeding. However, caution is needed in its use, especially in women with heart disease or hypovolemia. Misoprostol, a prostaglandin E1 analogue, can reduce bleeding during myomectomy by promoting myometrial contractions and reducing uterine artery blood flow. It can be administered via multiple routes, with rectal administration showing advantages in maintaining high plasma concentrations during surgery. Studies have investigated the effectiveness of single preoperative rectal doses of misoprostol versus preoperative oxytocin in reducing bleeding during abdominal myomectomy.

NCT ID: NCT06269809 Recruiting - Fibroid Uterus Clinical Trials

Temporary Artery Clipping for Robotically-assisted Myomectomy, a Multicentric Randomized Controlled Trial

TACROM
Start date: May 4, 2023
Phase: N/A
Study type: Interventional

This study aims to investigate the efficacy of temporary clipping of the uterine artery and utero-ovarian ligament during robotically assisted myomectomy (RAM) for uterine fibroids. While RAM is increasingly used for myomectomy, bleeding control remains challenging. Temporary clipping of arteries has shown promise in conventional laparoscopy but has not been studied in RAM. This randomized controlled trial will assess primary endpoints such as estimated blood loss, need for transfusion, and hemoglobin drop, alongside secondary outcomes like complication rates and operation time.

NCT ID: NCT06208891 Recruiting - Clinical trials for Women With Uterine Myoma

Clinical Outcomes of Robotic Myomectomy

Start date: November 21, 2023
Phase:
Study type: Observational

To identify the predictors of perioperative outcomes in women who receive robotic myomectomy

NCT ID: NCT06135870 Recruiting - Leiomyoma Clinical Trials

Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study)

SOUL
Start date: November 1, 2023
Phase:
Study type: Observational

The investigators are evaluating the role of senescent cells in uterine fibroids.

NCT ID: NCT06115408 Recruiting - Uterine Leiomyoma Clinical Trials

Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma

Start date: July 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This 2 arm randomized clinical trial will assess the impact of Dienogest and N-Acetyl Cysteine on volume reduction of uterine leiomyoma

NCT ID: NCT06106633 Recruiting - Uterine Fibroid Clinical Trials

Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization

PEDD-UFE
Start date: February 9, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to assess of Pressure-Enabled Drug Delivery on fibroid treatment in patients undergoing UFE.

NCT ID: NCT06099977 Recruiting - Prostate Cancer Clinical Trials

Binaural Sound for Remimazolam Induction

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

It is important to decrease the time-to-loss of consciousness and anesthetics dose of remimazolam for general anesthesia induction. We will evaluate the effect of binaural sound for general anestheia induction using remimazolam infusion.

NCT ID: NCT06067971 Recruiting - Myoma;Uterus Clinical Trials

Evaluation of the Feasibility of Using Augmented Reality in Laparoscopic Surgery, by a Clinical Study During Gynecological Laparoscopic Surgical Procedures. (ENDORA2)

ENDORA2
Start date: March 29, 2023
Phase: N/A
Study type: Interventional

Augmented Reality is a technology that allows surgeons to superimpose virtual images from preoperative imaging onto the endoscopic vision system intraoperatively. The goal of this clinical trial is to demonstrate that the use of augmented reality during laparoscopic gynecological surgery with a dedicated device could provide assistance to the surgeon, in terms of technical comfort and better visualization of the benign tumor to be resected on a mobile organ.

NCT ID: NCT06020924 Recruiting - Female Infertility Clinical Trials

The Effects of Uterine Fibroids on Pregnancy in Women

Start date: August 31, 2023
Phase:
Study type: Observational

Female fertility may be affected by uterine fibroids, although this association has not been elucidated. This retrospective cohort study aims to evaluate the impact of fibroids on women fertility.

NCT ID: NCT06009562 Recruiting - Pregnancy Related Clinical Trials

Management of Symptomatic Uterine Fibroids in Pregnancy by Laparotomic Myomectomy: a Prospective Cohort Study

LPTM-UFs-P
Start date: August 19, 2023
Phase:
Study type: Observational [Patient Registry]

The frequency of women presenting with a combination of uterine fibroids and pregnancy is in-creasing nowadays. Uterine fibroids in pregnancy are an unfavorable condition in themselves and being reactive to hormonal stimuli, tending to grow, can generate symptoms of different lev-els of severity. Obstetrics and gynecologists are increasingly faced with the problem of clarifying the management tactics of pregnant patients with symptomatic fibroids, who may see their preg-nancy put at risk by these masses.